Grifols-Backed Biotech Sees Early Promise With Alzheimer's Vaccine
Executive Summary
Phase I results for Araclon Biotech's Alzheimer's disease vaccine, ABvac40 – the only vaccine data presented at this year's Alzheimer's Association International Conference – warrant further exploration of this innovative approach to the disease.
You may also be interested in...
After Solanezumab, What’s Next? Alzheimer’s Options Take The Stage At CTAD
Lilly will make its first presentation of solanezumab data from the recently failed Phase III EXPEDITION3 study during the Clinical Trials in Alzheimer’s Disease meeting where researchers will discuss amyloid beta and other hypotheses in Alzheimer’s disease Dec. 8-10 in San Diego.
Janssen picks up AC Immune's Alzheimer's vaccine
AC Immune has signed a license agreement with Johnson and Johnson subsidiary Janssen, worth a potential $509m, to develop its Alzheimer's disease vaccine candidates.
Snapshot: April Highlights
A selection of articles you might have missed from April 2022, including exclusive interviews, an in depth look at the impact of COVID-19 on clinical trial trends, and the latest Rising Leaders series.